BioSpace News Archive

Funding completes $82 million Series B round with the addition of $19 million, will further accelerate Aetion’s role as a global leader in regulatory-grade evidence

It’s time to end the stigma of mental health in the black communities and start addressing our traumas so we can work collectively, productively and fruitfully, to contribute to wealth building in our communities. Abu Simbel, LLC event company

OPTEC International Inc., (OTC:OPTI) Today announced the company has now secured the expanded exclusive distribution rights for the North America regions for the OPTEC Hydroxyl sterilizer products.

Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the European Commission has granted conditional approval for IdefirixTM in highly sensitized kidney transplants patients.

Odonate Therapeutics, Inc., a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, announced that it has commenced an underwritten public offering of shares of its common stock.

New COVID-19 projections released by PolicyLab at Children’s Hospital of Philadelphia reveal large Midwestern cities will likely enter the fall with weekly case incidence counts nearly 10 times the rate of infection as when many European economies and schools reopened last spring.

Webcast to be held September 2, 2020 at 4:30 pm ET

FDA Approves Foundation Medicine’s FoundationOne ® Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer FDA Approval Includes Companion Diagnostic Claims for Rubraca ® (rucaparib), the First PARP Inhibitor Approved in a Prostate Cancer Setting, and Three Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer FoundationOne Liquid CDx Analyzes More Than 300 Genes a

Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that, due to demand, the underwriter has agreed to increase the size of its previously announced public offering and purchase on a firm commitment basis 14,285,715 shares of common stock of the Company

Verndari, Inc., a biopharmaceutical company transforming vaccines with next generation science and delivery technology, announced today a federal government award to support development of Verndari’s VaxiPatch™ alternative vaccine technology.